VolitionRx Limited (NYSE:VNRX) Q4 2020 Results Conference Call March 23, 2021 8:00 AM ET Company Participants Scott Powell - Investor Relations Cameron Reynolds - President and Chief Executive Officer Terig Hughes - Chief Financial Officer Dr. Jake Micallef - Chief Scientific Officer Conference Call Participants Kyle Mikson - Cantor Fitzgerald Jason McCarthy - Maxim Group Nathan Weinstein - Agesi Capital Bruce Jackson - Benchmark Company Operator Good morning, ladies and gentlemen, and thank you for standin ...

Volition© 2021 March 2021 Corporate Presentation Forward Looking Statements and Disclaimer Statements in this document may be "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that concern matters that involve risks and uncertainties that could cause actual results to differ materially from those anticipated or projected in the forward-looking statements. Words such as "expects," "anti ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 [X] For the Fiscal Year Ended December 31, 2020 TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 [ ] For the transition period from _____ to ______ Commission File Number: 001-36833 VOLITIONRX LIMITED (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorpor ...

VolitionRx Ltd. (NYSE:VNRX) Q3 2020 Earnings Conference Call November 13, 2020 8:30 AM ET Company Participants Scott Powell - EVP, IR Cameron Reynolds - President and CEO David Vanston - CFO Jason Terrell - Chief Medical Officer Conference Call Participants Jason McCarthy - Maxim Group Kyle Mikson - Cantor Fitzgerald Bruce Jackson - Benchmark Company Jason Kolbert - Dawson James Steven Ralston - Zacks Investment Research Operator Good morning, ladies and gentlemen, and thank you for standing by. Welcome to ...

Volition© 2020 Corporate Presentation November 2020 Forward Looking Statements and Disclaimer Statements in this document may be "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that concern matters that involve risks and uncertainties that could cause actual results to differ materially from those anticipated or projected in the forward-looking statements. Words such as "expects," "a ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______ to _____ Commission File Number: 001-36833 VOLITIONRX LIMITED (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of ...

VolitionRx Limited (NYSE:VNRX) Q2 2020 Earnings Conference Call August 14, 2020 8:30 AM ET Company Participants Scott Powell – Executive Vice President-Investor Relations Cameron Reynolds – President and Chief Executive Officer Conference Call Participants Mike Okunewitch – Maxim Group Mark Briedenbach – Oppenheimer & Company Bruce Jackson – The Benchmark Company Nathan Weinstein – Aegis Capital Steven Ralston – Zacks Operator Good morning, ladies and gentlemen, and thank you for standing by. Welcome to the ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______ to _____ Commission File Number: 001-36833 VOLITIONRX LIMITED (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of inco ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______ to _____ Commission File Number: 001-36833 VOLITIONRX LIMITED (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of inc ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Delaware (State or other jurisdiction of incorporation or organization) 13215 Bee Cave Parkway Suite 125, Galleria Oaks B Austin, Texas 78738 (Address of principal executive offices) +1 (646) 650–1351 FORM 10-K [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2019 [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For ...